Vaxxinity Inc (VAXX) AI Stock Analysis

• Market Cap: $2.11M
• Dividend Yield: N/A
• Average Volume (3M): 5.90K
• Price to Earnings (P/E): ―
• Beta (1Y): -171.96
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 126,784,680
• 10 Day Avg. Volume: 7,090
• 30 Day Avg. Volume: 5,904
• PEG Ratio: >-0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Vaxxinity Inc's overall score reflects its severe financial difficulties, lack of technical analysis data, and poor valuation metrics. The company's high financial leverage, persistent losses, and cash flow challenges significantly weigh down the score. With no guidance or sentiment from recent earnings calls, there is little to offset these concerns.

Vaxxinity Inc Business Overview & Revenue Model

Company Description

Vaxxinity Inc (VAXX) is a biotechnology company focused on the development of vaccines and therapeutics for the treatment of chronic diseases. The company leverages its proprietary synthetic peptide vaccine platform to create a new class of medicines aimed at transforming the treatment landscape for neurodegenerative diseases, infectious diseases, and other chronic illnesses. Vaxxinity's core products are designed to harness the body's immune response to target and manage disease progression.

How the Company Makes Money

Vaxxinity Inc generates revenue primarily through the development and commercialization of its vaccine candidates. The company aims to advance its pipeline of vaccine products through clinical trials and regulatory approvals, ultimately leading to commercialization. Revenue streams may include licensing agreements, partnerships with pharmaceutical companies, and sales of approved products. Key factors contributing to its earnings include successful clinical trial outcomes, strategic collaborations, and securing funding or grants for research and development. Additionally, Vaxxinity might engage in partnerships with healthcare organizations or governments for the distribution and supply of its vaccines.

Vaxxinity Inc Financial Statement Overview

Summary

Vaxxinity Inc faces significant financial challenges with no revenue growth, high leverage, and negative cash flows. The income statement shows zero revenue and consistent losses, the balance sheet indicates high financial leverage, and the cash flow statement reflects ongoing operational challenges.

Income Statement

Vaxxinity Inc shows a challenging income statement with zero revenue in recent years and consistently negative net income. The company has struggled with profitability, reflected in negative EBIT and EBITDA margins. The lack of revenue growth and continuous losses indicate a need for significant improvement in revenue generation and cost management.

Balance Sheet

The balance sheet of Vaxxinity Inc reveals a high debt-to-equity ratio due to substantial liabilities compared to equity, suggesting high financial leverage. The equity ratio has been weak, reflecting a dependence on debt financing. Despite these weaknesses, the company maintains a decent cash position relative to total assets, providing some liquidity cushion.

Cash Flow

Vaxxinity Inc's cash flow statement shows persistent negative operating and free cash flows, reflecting ongoing operational challenges. The operating cash flow to net income ratio is negative, indicating cash outflows from operations. The negative free cash flow growth rate further highlights financial strain. Despite these issues, the company has managed some positive financing cash flow in prior years.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	66.00K	557.00K	0.00
	Gross Profit
-2.23M	-1.68M	-1.87M	505.00K	-107.00K
	EBIT
-58.28M	-75.98M	-125.08M	-32.28M	-13.66M
	EBITDA
-56.05K	-74.30M	-135.23M	-31.57M	-13.58M
	Net Income Common Stockholders
-56.93K	-75.21M	-138.01M	-35.38M	-14.22M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
30.50M	86.83M	144.88M	31.14M	476.00K
	Total Assets
44.31M	106.40M	166.67M	50.14M	1.59M
	Total Debt
15.17M	14.55M	10.70M	38.30M	14.33M
	Net Debt
10.13M	-18.93M	-134.19M	7.16M	13.86M
	Total Liabilities
30.90M	44.22M	38.05M	137.52M	50.11M
	Stockholders Equity
13.41M	62.18M	128.62M	-87.38M	-48.51M
Cash Flow		Free Cash Flow
-58.04M	-57.79M	-82.31M	-35.39M	-12.27M
	Operating Cash Flow
-57.24M	-55.93M	-80.99M	-33.91M	-12.27M
	Investing Cash Flow
28.84M	-54.39M	-1.32M	-1.48M	0.00
	Financing Cash Flow
-1.14M	-167.00K	196.17M	66.11M	11.14M

Vaxxinity Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVAX	58 Neutral	$1.09B	2.54	30.06%	―	25.92%	―
BNTX	55 Neutral	$22.30B	―	-3.87%	―	0.58%	-764.64%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
VIR	44 Neutral	$635.89M	―	-44.59%	―	-73.79%	-5.24%
MRNA	43 Neutral	$9.61B	―	-29.34%	―	-38.25%	44.29%
PGEN	41 Neutral	$428.01M	―	-278.55%	―	-22.76%	-46.69%
VAXX	26 Underperform	$2.11M	―	-0.42%	―	―	―